Schafer, Galante, and Shafrin in JMCP: New Precision Survey Provides Insight Into Payer Use of Value Tools

In the current supplemental issue of Journal of Managed Care & Specialty Pharmacy (JMCP), Precision’s Jeremy Schafer, Dominic Galante, and Jason Shafrin share results of a recent survey of payers discerning payers’ use of value tools in healthcare decision-making.
Precision’s Abhishek Sharma Selected for World Heart Federation’s Emerging Leaders Program

Congratulations to Associate Health Economist Abhishek Sharma, part of Precision’s Evidence Strategy, Generation, and Communications team, for his acceptance into the World Heart Federation’s Emerging Leaders (EL) program. The program is part of a WHF initiative to reduce premature mortality from noncommunicable, chronic diseases by 25% by 2025. (more…)
Schafer and Serluco Emphasize the Importance of Immunotherapies in Specialty Pharmacy News
![]()
In the latest edition of Specialty Pharmacy News, Precision for Value’s Jeremy Schafer and Janet Serluco discuss their recent payer survey reflecting strong concerns over immunotherapy combination costs and usage. The authors suggest that building payer engagement with the provider community is one key to managing combination treatments.
Precision’s Font at Asembia Summit: The Real Payers Are Employers

At the Asembia Specialty Pharmacy Summit 2017, Precision for Value’s Jorge Font spoke about his presentation with Marie Rosenthal from Specialty Pharmacy Continuum on the significant impact big employers are having in revising the approaches to specialty pharmacy benefit administration and pricing. Font shared his perspective that the real payers are, in fact, employers.
Jeremy Schafer Discusses New HCV Survey in Managed Healthcare Executive Uncovering Unmet Needs of Payers

Precision for Value’s Jeremy Schafer talks with Managed Healthcare Executive about a recent Precision HCV survey, highlighting unmet needs cited by payers, and what can be done to encourage payers to ease coverage policies for the next wave of HCV drugs.